nach oben

Erschienen in:

01.06.2019 | Clinical study

Cardiovascular AEs more common with carfilzomib than bortezomib

Erschienen in: Reactions Weekly | Ausgabe 1/2019

Einloggen, um Zugang zu erhalten

Excerpt

Cardiovascular adverse events (CVAEs) occur frequently in patients with relapsed multiple myeloma receiving proteasome inhibitors (PIs), but are more common with carfilzomib than bortezomib, according to findings of the PROTECT (Prospective Observation of Cardiac Safety With Proteasome Inhibitor) study published in the Journal of Clinical Oncology. …

Cornell RF, et al. Prospective Study of Cardiac Events During Proteasome Inhibitor Therapy for Relapsed Multiple Myeloma Journal of Clinical Oncology : 12 Jun 2019. Available from: URL: http://doi.org/10.1200/JCO.19.00231

Titel: Cardiovascular AEs more common with carfilzomib than bortezomib
Publikationsdatum: 01.06.2019
Verlag: Springer International Publishing
Erschienen in: Reactions Weekly / Ausgabe 1/2019
Print ISSN: 0114-9954
Elektronische ISSN: 1179-2051
DOI: https://doi.org/10.1007/s40278-019-63895-8

Springer Medizin

Cardiovascular AEs more common with carfilzomib than bortezomib

Excerpt

Weitere Artikel der Ausgabe 1/2019

Tigecycline

Prednisone

Fluvoxamine overdose

Rivaroxaban

Sertraline/trazodone

Mercaptopurine

Springer Medizin

Excerpt

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Tigecycline

Prednisone

Fluvoxamine overdose

Rivaroxaban

Sertraline/trazodone

Mercaptopurine